Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


From Public To Private, Crossover Investors Are Back In Biotech

Executive Summary

Armed with cash from a robust M&A and a stock market boom, mutual and hedge funds are eagerly crossing over into mezzanine rounds for private biotechs and playing key roles in some of the year’s biggest venture financings.

You may also be interested in...

On The Road And Through The Window: Inside Three Biotech IPOs

Ophthotech, OncoMed, and bluebird bio are three of the dozens of biotechs that have made public debuts this year. Here’s how they did it, and the decisions they made to take advantage of being in the right place at the right time.

In Quest To Transform Biotech, Moderna Secures $110M To Get Into Clinic

This biotech envisions a day when messenger RNA therapeutics enable a patient’s body to produce needed proteins in vivo, thereby vastly expanding the universe of druggable targets and bypassing all of the patented large-molecule drugs that are the industry’s foundation.

No Zafgen IPO Yet; It Plans a $40M Crossover Round

The private obesity company will do a mezzanine venture financing that brings in at least one public-oriented investor before it heads, presumably, toward an IPO. That round is slated to close in a month or so. Around the same time, Zafgen will present final Phase II data for its beloranib.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts